Aerie Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Aerie Pharmaceuticals Inc.
Hartford Mid Cap Fund
1,806,237
3.99%
90,142
0.84%
07/31/2018
Vanguard Small Cap Index Fund
994,162
2.2%
13,112
0.06%
07/31/2018
Vanguard Total Stock Market Index Fund
987,417
2.18%
920
0.01%
07/31/2018
iShares Russell 2000 ETF
746,674
1.65%
-399
0.09%
09/06/2018
Prudential Jennison Health Sciences Fund
737,521
1.63%
0
1.77%
07/31/2018
Vanguard Small Cap Value Index Fund
624,714
1.38%
6,306
0.12%
07/31/2018
Fidelity Select Biotechnology Portfolio
621,425
1.37%
0
0.42%
07/31/2018
Vanguard Extended Market Index Fund
522,807
1.15%
2,100
0.05%
07/31/2018
iShares Nasdaq Biotechnology ETF
522,638
1.15%
-6,825
0.33%
09/06/2018
Invesco Small Cap Growth Fund
419,503
0.93%
54,840
0.78%
06/29/2018
| Address |
4301 Emperor Boulevard
Durham North Carolina 27703
United States
|
|
Employees
|
- |
| Website |
http://www.aeriepharma.com |
| Updated |
07/08/2019 |
| Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan. The company was founded by David L. |
